Home Alzheimer’s Disease Guidelines for Palliative Treatment of Spinal Metastases: Choosing Between Stereotactic Body Radiation...

Guidelines for Palliative Treatment of Spinal Metastases: Choosing Between Stereotactic Body Radiation Therapy and Conventional Fractionation

Background

Spinal metastasis is noted in many common primary cancer sites such as breast, prostate, and lung, making palliation of symptomatic spinal metastases both a frequent and heterogeneous indication for radiation therapy.1

Historically, palliative radiation therapy for spinal disease was delivered using 2-dimensional (2D) planning techniques that delivered moderate doses of radiation to the involved portion of the spine over 5 to 15 treatments; beams coming from the anterior and posterior directions were placed and shaped using the location of involved spinal levels on a radiograph.2,3 Treatment with 2D technique is limited both by the detail provided by radiographs and the inability to spare the spinal cord and viscera located near the treatment target. Over time, the advent of CT and MRI, along with paradigm-shifting improvements in radiation planning and delivery…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments